glp-1 activator lifevantage GLP-ONE + Receptor Support Your Wellness with LifeVantage

Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial

Study participants experienced increases in urinary melatonin metabolites and meaningful improvements in neuromuscular function

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance

The headline claims LifeVantage reports the following results from their clinical research: 200%+ average increase in GLP-1 levels Average weight loss of 11 pounds in 12 weeks, with some participants losing up to 25 pounds 100% of participants who lost weight maintained muscle mass Up to 6% total body fat percentage lost Up to 24% visceral fat reduction 86% decreased food, salt, and soda cravings 95% decreased sugar cravings 89% decreased fast food cravings These numbers look impressive at first glance

For decades, it seemed that rising population-level weight gain in the US was an unavoidable pattern